Nirsevimab and Avrexy were shown to be 83% and 67% effective at preventing hospitalization, respectively.
Though the KP.3.1.1 variant is still dominant, levels of the newer XEC variant continue to rise.
One clade of eight RSV-B genomes had a mutation tied to resistance to the monoclonal antibody nirsevimab.
The authors said they observed distinct regional patterns to norovirus outbreaks in the state.
The CDC said the rise in M pneumoniae in children ages 2 to 4 is notable, because it isn't typically known as a leading cause of pneumonia in the age-group.
The authors said the findings should encourage people to get vaccinated against RSV this year.
Less than half recognized some of the most common infant RSV symptoms.
There were no known nirsevimab resistance–associated mutations in infections caused by RSV-A.
The authors found airway NK cells were increased in intubated children.
The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.
